Treatment of steroid-induced osteopenia with calcitonin in corticosteroid-dependent asthma. A one-year follow-up study.

Luengo M, Picado C, Del Rio L, Guañabens N, Montserrat JM, Setoain J

The American review of respiratory disease1 Jul 1990Cited by 59 (Europe PMC)

PMID2195929DOI10.1164/ajrccm/142.1.104PepBankPUB-02195929

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanNon-randomized trialEfficacy outcome
In steroid-dependent asthmatics, bone mineral density at one year increased by a mean of 4% with calcium plus salmon calcitonin and decreased by 2.5% with calcium alone.
In plain wordsIn steroid-dependent asthmatics, bone density increased with salmon calcitonin, while calcium-only controls lost bone density.
Peptide
Calcitonin-salmon
Outcome
IncreaseBone mineral density
Study
n = 40
Comparator
Calcium supplementation alone
Outcome group
Bone and joint · Musculoskeletal
Studied dose
100 IU every other day · subcutaneous · 12 monthsAs given in this study (human).
Measurements
BMD change
4%
calcitonin
BMD change
−2.5%
calcium-only control
Source sentences
Summary
At one year, bone mineral density (BMD) had increased in the calcitonin group by a mean of 4% (p less than or equal to 0.001), whereas in the control group BMD had decreased by 2.5% (p less than or equal to 0.05).
4 context sentences(design, population, supporting numbers)
Summary · context
The 20 patients who completed the 12-month follow-up period were analyzed and compared with 20 sex-matched patients from the control group.
Summary · context
Sixty-two steroid-dependent asthmatics who had not received any form of treatment to prevent bone loss were studied during a 12-month period.
Summary · context
Patients were randomly divided into two groups.
Summary · context
Thirty-one patients were treated with 1 g of elemental calcium taken daily plus 100 IU of salmon calcitonin every other day, administered subcutaneously; the remaining 31 patients received only calcium supplementation.
Report a problemFND-0219592901
02HumanNon-randomized trialEfficacy outcome
In steroid-dependent asthmatics, alkaline phosphatase decreased significantly with salmon calcitonin but not with calcium alone.
In plain wordsIn steroid-dependent asthmatics, alkaline phosphatase decreased with salmon calcitonin but not with calcium alone.
Peptide
Calcitonin-salmon
Outcome
DecreaseAlkaline phosphatase
Study
n = 40
Comparator
Calcium supplementation alone
Outcome group
Bone and joint · Musculoskeletal
Studied dose
100 IU every other day · subcutaneous · 12 monthsAs given in this study (human).
Source sentences
Summary
Parameters of bone remodeling (alkaline phosphatase and osteocalcin) decreased significantly in the calcitonin-treated group but not in the control group.
4 context sentences(design, population, supporting numbers)
Summary · context
The 20 patients who completed the 12-month follow-up period were analyzed and compared with 20 sex-matched patients from the control group.
Summary · context
Sixty-two steroid-dependent asthmatics who had not received any form of treatment to prevent bone loss were studied during a 12-month period.
Summary · context
Patients were randomly divided into two groups.
Summary · context
Thirty-one patients were treated with 1 g of elemental calcium taken daily plus 100 IU of salmon calcitonin every other day, administered subcutaneously; the remaining 31 patients received only calcium supplementation.
Report a problemFND-0219592902
03HumanNon-randomized trialEfficacy outcome
In steroid-dependent asthmatics, osteocalcin decreased significantly with salmon calcitonin but not with calcium alone.
In plain wordsIn steroid-dependent asthmatics, osteocalcin decreased with salmon calcitonin but not with calcium alone.
Peptide
Calcitonin-salmon
Outcome
DecreaseOsteocalcin
Study
n = 40
Comparator
Calcium supplementation alone
Outcome group
Bone and joint · Musculoskeletal
Studied dose
100 IU every other day · subcutaneous · 12 monthsAs given in this study (human).
Source sentences
Summary
Parameters of bone remodeling (alkaline phosphatase and osteocalcin) decreased significantly in the calcitonin-treated group but not in the control group.
4 context sentences(design, population, supporting numbers)
Summary · context
The 20 patients who completed the 12-month follow-up period were analyzed and compared with 20 sex-matched patients from the control group.
Summary · context
Sixty-two steroid-dependent asthmatics who had not received any form of treatment to prevent bone loss were studied during a 12-month period.
Summary · context
Patients were randomly divided into two groups.
Summary · context
Thirty-one patients were treated with 1 g of elemental calcium taken daily plus 100 IU of salmon calcitonin every other day, administered subcutaneously; the remaining 31 patients received only calcium supplementation.
Report a problemFND-0219592903
04HumanNon-randomized trialSafety outcome
In steroid-dependent asthmatics, 11 calcitonin recipients withdrew: seven for severe side effects, three for noncompliance, and one for asthma exacerbation.
In plain wordsEleven calcitonin recipients withdrew, including seven for severe side effects, three for noncompliance, and one for asthma exacerbation.
Peptide
Calcitonin-salmon
Outcome
Not applicableTreatment withdrawal
Study
n = 31
Outcome group
Adverse events · Whole body
Studied dose
100 IU every other day · subcutaneous · 12 monthsAs given in this study (human).
Measurements
Patients who dropped out
11 patients
calcitonin group
Dropouts due to severe side effects
7 patients
calcitonin group
Dropouts due to lack of compliance
3 patients
calcitonin group
Dropouts due to asthma exacerbation
1 patients
calcitonin group
Source sentences
Summary
In the calcitonin group, 11 patients dropped out of the study because of severe side effects (seven patients), lack of compliance (three patients), and exacerbation of asthma (one patient).
3 context sentences(design, population, supporting numbers)
Summary · context
Sixty-two steroid-dependent asthmatics who had not received any form of treatment to prevent bone loss were studied during a 12-month period.
Summary · context
Patients were randomly divided into two groups.
Summary · context
Thirty-one patients were treated with 1 g of elemental calcium taken daily plus 100 IU of salmon calcitonin every other day, administered subcutaneously; the remaining 31 patients received only calcium supplementation.
Report a problemFND-0219592904
05HumanNon-randomized trialSafety outcome
In steroid-dependent asthmatics, seven calcitonin recipients withdrew because of severe side effects.
In plain wordsSeven calcitonin recipients with steroid-dependent asthma withdrew because of severe side effects.
Peptide
Calcitonin-salmon
Outcome
Not applicableSevere side effects
Study
n = 31
Outcome group
Adverse events · Whole body
Studied dose
100 IU every other day · subcutaneous · 12 monthsAs given in this study (human).
Measurements
Dropouts due to severe side effects
7 patients
calcitonin group
Source sentences
Summary
In the calcitonin group, 11 patients dropped out of the study because of severe side effects (seven patients), lack of compliance (three patients), and exacerbation of asthma (one patient).
3 context sentences(design, population, supporting numbers)
Summary · context
Sixty-two steroid-dependent asthmatics who had not received any form of treatment to prevent bone loss were studied during a 12-month period.
Summary · context
Patients were randomly divided into two groups.
Summary · context
Thirty-one patients were treated with 1 g of elemental calcium taken daily plus 100 IU of salmon calcitonin every other day, administered subcutaneously; the remaining 31 patients received only calcium supplementation.
Report a problemFND-0219592905
06HumanNon-randomized trialSafety outcome
In steroid-dependent asthmatics, one calcitonin recipient withdrew because of asthma exacerbation.
In plain wordsOne calcitonin recipient withdrew because asthma worsened.
Peptide
Calcitonin-salmon
Outcome
Not applicableAsthma exacerbation
Study
n = 31
Outcome group
Adverse events · Respiratory
Studied dose
100 IU every other day · subcutaneous · 12 monthsAs given in this study (human).
Measurements
Dropouts due to asthma exacerbation
1 patients
calcitonin group
Source sentences
Summary
In the calcitonin group, 11 patients dropped out of the study because of severe side effects (seven patients), lack of compliance (three patients), and exacerbation of asthma (one patient).
3 context sentences(design, population, supporting numbers)
Summary · context
Sixty-two steroid-dependent asthmatics who had not received any form of treatment to prevent bone loss were studied during a 12-month period.
Summary · context
Patients were randomly divided into two groups.
Summary · context
Thirty-one patients were treated with 1 g of elemental calcium taken daily plus 100 IU of salmon calcitonin every other day, administered subcutaneously; the remaining 31 patients received only calcium supplementation.
Report a problemFND-0219592906

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.